The company
MoonLake Immunotherapeutics - Class A
MLTX · Nasdaq
MLTX stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 10 weeks. It is 42.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 10
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $160.1M
- Officials’ trades on record
- 0
- Institutions holding
- 162 (+24)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Kristian ReichChief Scientific Officer | sold | 1,100at $20.00 | 27 Jul 2026filed 29 Jul 2026 |
| Kristian ReichChief Scientific Officer | sold | 2,448at $20.00 | 22 Jul 2026filed 23 Jul 2026 |
| Kristian ReichChief Scientific Officer | sold | 50,000at $20.02 | 21 Jul 2026filed 23 Jul 2026 |
| Kristian ReichChief Scientific Officer | sold | 43,700at $20.09 | 20 Jul 2026filed 21 Jul 2026 |
| Kristian ReichChief Scientific Officer | sold | 16,105at $20.01 | 15 Jul 2026filed 20 Jul 2026 |
| Da Silva Jorge SantosChief Executive Officer | sold | 68,289at $20.02 | 10 Jul 2026filed 13 Jul 2026 |
| Da Silva Jorge SantosChief Executive Officer | sold | 33,936at $20.01 | 9 Jul 2026filed 13 Jul 2026 |
| Da Silva Jorge SantosChief Executive Officer | sold | 47,775at $20.03 | 1 Jul 2026filed 2 Jul 2026 |
| Matthias BodenstedtChief Financial Officer | sold | 39,120at $22.04 | 22 Jun 2026filed 23 Jun 2026 |
| Matthias BodenstedtChief Financial Officer | sold | 2,794at $19.60 | 18 Jun 2026filed 18 Jun 2026 |
| Kristian ReichChief Scientific Officer | sold | 50,000at $19.43 | 17 Jun 2026filed 17 Jun 2026 |
| Matthias BodenstedtChief Financial Officer | sold | 15,082at $19.68 | 17 Jun 2026filed 18 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BVF INCunchanged · filed 14 Aug 2026 | 16,001,284$311.5M | 00.0% |
| Deep Track Capital, LPadded · filed 14 Aug 2026 | 6,999,025$136.3M | +590,162+9.2% |
| D. E. Shaw & Co., Inc.added · filed 14 Aug 2026 | 3,365,507$65.5M | +974,846+40.8% |
| Cormorant Asset Management, LPreduced · filed 14 Aug 2026 | 3,205,433$62.4M | -1,275,000−28.5% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 3,085,906$60.1M | +3,085,906 |
| Logos Global Management LPadded · filed 14 Aug 2026 | 2,675,000$52.1M | +1,175,000+78.3% |
| Weiss Asset Management LPadded · filed 14 Aug 2026 | 2,581,813$50.3M | +873,485+51.1% |
| CITADEL ADVISORS LLCadded · filed 14 Aug 2026 | 1,972,893$38.4M | +649,165+49.0% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 1,715,349$33.4M | +593,037+52.8% |
| MPM BIOIMPACT LLCreduced · filed 14 Aug 2026 | 1,606,967$31.3M | -204,115−11.3% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.